CLAIMS

1. The use of milk in the manufacture of a composition for preventing or reducing the risk of inflammation of the colon that is induced by beta-casomorphin-7 (BCM-7) in a human, wherein the composition contains beta-casein and wherein the beta-casein comprises at least 90% by weight beta-casein A2 and less than 10% by weight beta-casein A1,

   wherein the composition is bovine milk or a bovine milk product, and

   wherein the preventing or reducing the risk of inflammation of the colon involves consumption of the composition, thereby reducing or eliminating beta-casein A1 in a diet of the human.

2. The use as claimed in claim 1, wherein the beta-casein comprises at least 99% beta-casein A2.

3. The use as claimed in claim 1 or claim 2, wherein the beta-casein comprises less than 1% by weight beta-casein A1.

4. The use as claimed in any one of claims 1 to 3, wherein the milk is fresh milk, milk powder, liquid milk reconstituted from powder, skim milk, homogenised milk, condensed milk, evaporated milk, pasteurised milk, non-pasteurised milk, or UHT milk.

5. The use as claimed in any one of claims 1 to 3, wherein the milk product is cream, yoghurt, quark, cheese, butter, or ice cream.

6. The use as claimed in any one of claims 1 to 5, wherein the inflammation of the colon is an inflammatory bowel disease.

7. The use as claimed in claim 6, wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis.

8. The use as claimed in any one of claims 1 to 5, wherein the inflammation of the bowel is irritable bowel syndrome.